ACADIA Pharmaceuticals Inc. (ACAD) Stock Analysis
Falling Knife setup
Healthcare · Biotechnology
Sell if holding. Momentum 2.2/10 is below the 5.0 floor at $20.67 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Leverage penalty (D/E 4.1): -1.5; Cyclical risk: PE expanding 2.5x (earnings normalizing).
ACADIA Pharmaceuticals is a commercial-stage biopharmaceutical company with two FDA-approved neurological products: NUPLAZID (the only approved treatment for Parkinson's disease psychosis) and DAYBUE (the only approved treatment for Rett syndrome). Combined net product sales... Read more
Sell if holding. Momentum 2.2/10 is below the 5.0 floor at $20.67 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Leverage penalty (D/E 4.1): -1.5; Cyclical risk: PE expanding 2.5x (earnings normalizing). Chart setup: Death cross, below all MAs, RSI 34, MACD bearish. Score 5.2/10, moderate confidence.
Passes 6/9 gates (favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity 78d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: aggressive.
Recent Developments — ACADIA Pharmaceuticals Inc.
Latest news
- Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance — Yahoo Finance positive
- ACADIA Pharmaceuticals (ACAD) to Release Earnings on Wednesday - MarketBeat — MarketBeat neutral
- ACADIA PHARMACEUTICALS ($ACAD) Releases Q1 2026 Earnings - Quiver Quantitative — Quiver Quantitative neutral
- R&D Leadership Transition and Trial Continuity Could Be A Game Changer For ACADIA Pharmaceuticals (ACAD) - Sahm — Sahm positive
- Acadia Pharmaceuticals CFO Mark Schneyer sells $76,395 in stock - Investing.com — Investing.com negative
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 2.2/10 is below the 5.0 floor at $20.67 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Leverage penalty (D/E 4.1): -1.5; Cyclical risk: PE expanding 2.5x (earnings normalizing). Chart setup: Death cross, below all MAs, RSI 34, MACD bearish. Prior stop was $20.03. Score 5.2/10, moderate confidence.
Take-profit target: $28.48 (+37.7% upside). Prior stop was $20.03. Stop-loss: $20.03.
Cyclical risk: PE expanding 2.5x (earnings normalizing); Leverage penalty (D/E 4.1): -1.5; Weak growth.
ACADIA Pharmaceuticals Inc. trades at a P/E of 9.4 (forward 23.2). TrendMatrix value score: 6.6/10. Verdict: Sell.
27 analysts cover ACAD with a consensus score of 4.0/5. Average price target: $32.
What does ACADIA Pharmaceuticals Inc. do?ACADIA Pharmaceuticals is a commercial-stage biopharmaceutical company with two FDA-approved neurological products:...
ACADIA Pharmaceuticals is a commercial-stage biopharmaceutical company with two FDA-approved neurological products: NUPLAZID (the only approved treatment for Parkinson's disease psychosis) and DAYBUE (the only approved treatment for Rett syndrome). Combined net product sales were $1,071.5M in 2025; remlifanserin (Phase 2) for Alzheimer's disease psychosis is the most advanced pipeline candidate with data readout expected Aug-Oct 2026.